<bill session="116" type="s" number="2246" updated="2020-12-28T14:37:39Z">
  <state datetime="2019-07-24">REFERRED</state>
  <status>
    <introduced datetime="2019-07-24"/>
  </status>
  <introduced datetime="2019-07-24"/>
  <titles>
    <title type="official" as="introduced">A bill to amend titles XVIII and XIX of the Social Security Act to provide equal coverage of in vitro specific IgE tests and percutaneous tests for allergies under the Medicare and Medicaid programs, and for other purposes.</title>
    <title type="display">Allergy Testing Access Act of 2019</title>
    <title type="short" as="introduced">Allergy Testing Access Act of 2019</title>
  </titles>
  <sponsor bioguide_id="M000934"/>
  <cosponsors>
    <cosponsor bioguide_id="B000944" joined="2020-01-15"/>
    <cosponsor bioguide_id="C001047" joined="2019-11-13"/>
    <cosponsor bioguide_id="C001113" joined="2019-10-31"/>
    <cosponsor bioguide_id="M001169" joined="2019-10-22"/>
    <cosponsor bioguide_id="P000595" joined="2019-12-03"/>
    <cosponsor bioguide_id="S001184" joined="2020-10-20"/>
  </cosponsors>
  <actions>
    <action datetime="2019-07-24">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2019-07-24" state="REFERRED">
      <text>Read twice and referred to the Committee on Finance.</text>
    </action>
  </actions>
  <committees>
    <committee subcommittee="" code="SSFI" name="Senate Finance" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill type="h" session="116" relation="unknown" number="2009"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Allergies"/>
    <term name="Health care costs and insurance"/>
    <term name="Health care coverage and access"/>
    <term name="Medicaid"/>
    <term name="Medical tests and diagnostic methods"/>
    <term name="Medicare"/>
  </subjects>
  <amendments/>
  <summary date="2019-07-24T04:00:00Z" status="Introduced in Senate">Allergy Testing Access Act of 2019

This bill requires equal coverage of two types of allergy tests under Medicaid and Medicare.

Specifically, in vitro specific IgE tests (blood tests) and percutaneous tests (skin tests) must be treated equally with respect to (1) medical necessity or other coverage requirements, (2) frequency limits, and (3) allergen unit limits.</summary>
  <committee-reports/>
</bill>
